lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Effect of the Third Dose of Astrazeneca Vaccine on the Ability to Generate Anti-Rbd Antibodies within Two At-Risk Populations, Geriatrics and Health Personnel in the Province of Tucumán

23 Pages Posted: 21 Apr 2022

See all articles by Luis Medina Ruiz

Luis Medina Ruiz

Argentina Ministry of Health-Ministerio de Salud Argentina

Miguel Ferre Contreras

Argentina Ministry of Health-Ministerio de Salud Argentina

Eliana Molina

affiliation not provided to SSRN

Mónica Aguilar López

Néstor Kirchner Hospital - Central Public Health laboratory (LSP) (SIPROSA)

Dardo Costa

Néstor Kirchner Hospital - Central Public Health laboratory (LSP) (SIPROSA)

Patricia Aznar

Néstor Kirchner Hospital - Central Public Health laboratory (LSP) (SIPROSA)

María Elena Alcorta

Néstor Kirchner Hospital - Central Public Health laboratory (LSP) (SIPROSA)

Laura Lara

Argentina Ministry of Health-Ministerio de Salud Argentina

Guillermo Gabriel Barrenechea

Argentina Ministry of Health-Ministerio de Salud Argentina

Eugenia Silvana Ortega

Argentina Ministry of Health-Ministerio de Salud Argentina

Maria de los Angeles Peral de Bruno

Argentina Ministry of Health-Ministerio de Salud Argentina

More...

Abstract

This study aims to evaluate the effect on the ability to generate Anti-Anti RBD antibodies (Anti-SAR-CoV 2-Spike-RBD) to the third dose of the AstraZeneca vaccine in two at-risk populations in the Province of Tucumán. Humoral immune responses, assayed by anti-SARS-CoV-2-Spike-RBD IgG ELISA, were measured in 223 participants, including geriatric patients and healthcare workers, at 0, 14 and 28 days after receiving third dose of the AstraZeneca between October and December 2021 in Tucuman, Argentina. The antibodies title in geriatric patients with and without previous COVID-19 diseases and complete vaccine schedule increased significantly 14 days after receiving the third dose of the AstraZeneca vaccine (p<0.001). When compared Antibody Concentration in geriatric patients with and without a history of COVID-19 14 days post-vaccination, the increase in antibodies was higher in those who did not have a previous history of COVID-19 (p<0.05). The antibodies title in healthcare personnel with and without previous COVID-19 diseases and complete vaccination increased significantly 14 days post-vaccination with the third dose of AstraZeneca (p<0.01). There was a negative correlation between age and antibodies titer 14 days after the third dose of COVID vaccine in persons with no history of disease (rs= -0.36, p=0.0001). While persons with a history of COVID-19 did not have a significant correlation (rs= -0.03; p=0.8). The results obtained provide information on antibodies dynamics after the third dose with AstraZeneca in a context of vaccine heterogeneity, indicating the importance of baseline studies of antibodies and hybrid immunity when considering vaccination policies.

Funding Information: Not applicable.

Declaration of Interests: The authors did not receive any monetary compensation for this work. They declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethics Approval Statement: This study was approved by the Research Committee of the Public Health System of Tucumán. The Ethics Committee of the Ministry of Public Health of the Province of Tucumán evaluated and approved the research protocol of the present study. All enrolled volunteers were duly informed about their choice 220 to participate in the study and provided a signed informed consent.

Suggested Citation

Medina Ruiz, Luis and Ferre Contreras, Miguel and Molina, Eliana and Aguilar López, Mónica and Costa, Dardo and Aznar, Patricia and Alcorta, María Elena and Lara, Laura and Barrenechea, Guillermo Gabriel and Ortega, Eugenia Silvana and Peral de Bruno, Maria de los Angeles, Effect of the Third Dose of Astrazeneca Vaccine on the Ability to Generate Anti-Rbd Antibodies within Two At-Risk Populations, Geriatrics and Health Personnel in the Province of Tucumán. Available at SSRN: https://ssrn.com/abstract=4089493 or http://dx.doi.org/10.2139/ssrn.4089493

Luis Medina Ruiz

Argentina Ministry of Health-Ministerio de Salud Argentina

Miguel Ferre Contreras

Argentina Ministry of Health-Ministerio de Salud Argentina ( email )

Eliana Molina

affiliation not provided to SSRN ( email )

No Address Available

Mónica Aguilar López

Néstor Kirchner Hospital - Central Public Health laboratory (LSP) (SIPROSA) ( email )

Tucumán
Argentina

Dardo Costa

Néstor Kirchner Hospital - Central Public Health laboratory (LSP) (SIPROSA) ( email )

Tucumán
Argentina

Patricia Aznar

Néstor Kirchner Hospital - Central Public Health laboratory (LSP) (SIPROSA) ( email )

Tucumán
Argentina

María Elena Alcorta

Néstor Kirchner Hospital - Central Public Health laboratory (LSP) (SIPROSA) ( email )

Tucumán
Argentina

Laura Lara

Argentina Ministry of Health-Ministerio de Salud Argentina ( email )

Guillermo Gabriel Barrenechea

Argentina Ministry of Health-Ministerio de Salud Argentina

Eugenia Silvana Ortega

Argentina Ministry of Health-Ministerio de Salud Argentina

Maria de los Angeles Peral de Bruno (Contact Author)

Argentina Ministry of Health-Ministerio de Salud Argentina

Click here to go to TheLancet.com

Paper statistics

Abstract Views
73
Downloads
4
PlumX Metrics